NewAmsterdam Pharma Co N.V. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.39M-0.26M102.69M14.09M45.56M
Operating items
Research & Development 4.62M29.62M86.74M159.42M151.41M
Wages, Salaries and Other 0.30M1.91M5.12M
Selling, General & Administrative 1.58M5.68M19.51M37.63M70.45M
Operating Expenses 6.20M35.31M106.25M197.06M221.85M
Operating Income -6.20M-35.31M-3.56M-182.97M-176.29M
EBIT -6.20M-35.31M-3.56M-182.97M-176.29M
Non-operating items
Interest & Investment Income 0.01M0.01M11.28M16.88M
Other Non Operating Income 27.401.71M-9.75M10.02M38.58M
Net income details
EBT -6.56M-33.84M-22.63M-176.91M-241.60M
Tax Provisions 0.03M-0.00M
Profit After Tax -6.56M-33.84M-22.63M-176.94M-241.60M
Income from Continuing Operations -6.56M-33.84M-22.63M-176.94M-241.60M
Consolidated Net Income -6.56M-33.84M-22.63M-176.94M-241.60M
Income towards Parent Company -6.56M-33.84M-79.63M-176.94M-241.60M
Net Income towards Common Stockholders -6.56M-33.84M-79.63M-176.94M-241.60M
Additional items
EPS (Basic) -0.71-1.43-1.19-2.15-2.56
EPS (Weighted Average and Diluted) -0.71-1.43-1.19-2.15-2.56
Shares Outstanding (Weighted Average) 12.93M17.75M77.68M97.35M92.39M
Shares Outstanding (Diluted Average) 41.26M
EBITDA -0.01M-41.50M-11.51M-176.94M-241.55M
Interest Expenses 0.39M0.26M0.29M
Shares Outstanding 81.56M82.47M108.06M
Tax Rate 0.00